

慢性骨髓性白血病

論文

- Sato E, Iriyama N, Tokuhira M, et al. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med. 2020; 9: 8931-8939.
- Ishikawa M, Iriyama N, Tokuhira M, et al. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Oncol Rep. 2019; 42: 2836-2843.
- Iriyama N, Tokuhira M, et al. Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis. Hematol Oncol. 2019; 37: 323-325.
- Iriyama N, ..., Tokuhira M, et al. Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis. Med Oncol. 2018; 35: 142.
- Fujioka I, ..., Tokuhira M, et al. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol. 2018; 97: 2081-2088.
- Nakazato T, Iriyama N, Tokuhira M, et al. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Med Oncol. 2018; 35: 99.
- Takahashi N, ..., Tokuhira M, et al: Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018; 103: 1835-1842.
- Tokuhira M, et al. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol. 2018; 35: 38.
- Sato E, Iriyama N, Tokuhira M, et al. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score. Leuk Lymphoma. 2018; 59: 1105-1112.
- Iriyama N, Tokuhira M, et al. and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group. Leuk Res. 2017; 54: 55-58.

書籍、雑誌

- 得平道英：進行期(BP) 慢性骨髓性白血病、エビデンスに基づいた癌化学療法ハンドブック。大津敦編、メディカルレビュー社、大阪、pp. 836-838、2017.

- 得平道英、他：慢性期(初期治療の選択)、慢性骨髄性白血病・骨髄増殖性腫瘍. 木村文彦、他、編、最新医学社、大阪、pp. 101-109、2016.
- 得平道英、他：初発慢性期CML、慢性骨髄性白血病 (CML)の基礎と臨床. 松村到、他、編、医薬ジャーナル社、東京、pp. 87-102、2015.
- 得平道英：初発CML-CPの治療方針、EBM 血液疾患の治療 2015-2016. 木崎昌弘、他、編、中外医学社、東京、pp. 143-149、2014.
- 阿南 朋恵、得平道英、他：初発慢性期CMLの治療 血液内科 67: 144-151、2013.
- 得平道英、他：WHO分類に基づく骨髄増殖性腫瘍の分類と診断. 血液・腫瘍科 61: 131-139、2010.
- 得平道英、他：エビデンスに基づく骨髄増殖性疾患の病型移行の実際. カレントセラピー 26: 490-494、2008.
- 得平道英、他：骨髄増殖性疾患の新しい分類と診断: 2008 WHO分類. 血液・腫瘍科 57: 455-462、2008.
- 得平道英、他：慢性期CMLに対するイマチニブの効果はどのように評価すればよいか？ EBM 血液疾患の治療 2008-2009. 押見和夫、他、編、中外医学社、東京、pp. 247-52、2008.